Combination of a pd-1 antagonist and eribulin for treating cancer

An antagonist, PD-1 technology, applied in the field of combined therapy for the treatment of breast cancer, can solve problems such as impaired immune response

Active Publication Date: 2018-03-16
MERCK & CO INC +1
View PDF28 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, it has been proposed that PD-L1-expressing tumor cells interact with PD-1-expressing T cells to attenuate T-cell activation and cancer cell evasion of immune surveillance, thereby resulting in impaired immune responses against tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of a pd-1 antagonist and eribulin for treating cancer
  • Combination of a pd-1 antagonist and eribulin for treating cancer
  • Combination of a pd-1 antagonist and eribulin for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0219] Research design

[0220] The open-label, Single-arm, multicenter, phase 1b / 2 study. Figure 8 An example of the study design of a phase 1b / 2, open-label, single-arm, multicentre trial is shown. The number of subjects provided below for each phase of the study is a non-limiting example. Specific dosing regimens and / or amounts are also non-limiting. Those of ordinary skill in the art will appreciate that the number of subjects participating in a study can be increased or decreased. Those of ordinary skill in the art will understand how to modify dosing regimens and / or amounts for a particular patient or set of subjects.

[0221]Patients / patients can be included in the study if they have mTNBC previously treated with 0-2 lines of chemotherapy for metastatic disease. The presence of measurable disease can be defined as ≥1 of the following lesions: for non-lymph nodes, ≥10 mm long-axis diameter; or for lymph nodes, ≥15 mm short-axis diameter, which is serially measura...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD- 1 ) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Application 62 / 128,373, filed March 4, 2015, and US Provisional Application 62 / 264,068, filed December 7, 2015, the contents of which are hereby incorporated by reference in their entirety. [0003] sequence listing [0004] Also attached is a Sequence Listing comprising SEQ ID NOs: 1-25, which is hereby incorporated by reference in its entirety. technical field [0005] The present invention relates to combination therapies useful in the treatment of breast cancer. Specifically, the present invention relates to a combination therapy comprising an antagonist of programmed death 1 protein (PD-1) and eribulin or a pharmaceutically acceptable salt thereof. Background technique [0006] PD-1 is considered to play an important role in immune regulation as well as in the maintenance of peripheral tolerance. PD-1 is moderately expressed on naive T, B, and NKT cells and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/357A61K39/395A61P35/00A61P15/14
CPCA61K9/0019A61K31/357A61K45/06C07K16/2818A61K2039/505A61K2300/00A61P15/00A61P15/14A61P35/00A61P35/04A61P43/00A61K39/395A61K39/3955A61K39/39566
Inventor J.马特随G.阿克坦V.克兰察R.元Y.富纳哈施E.贝拉克
Owner MERCK & CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap